HPV is a common virus that is easily spread by skin-to-skin contact during sexual activity with another person, according to the CDC.
Currently, the CDC ACIP recommends the HPV vaccine for girls at ages 11 and 12 to “prevent serious health problems, such as cervical cancer in females and other, less common cancers, which are caused by HPV.” In 2009, the Food and Drug Administration licensed the HPV vaccine Gardasil® to prevent genital warts in men and boys, but the CDC has yet to weigh in regarding its recommendation.
Georgetown University School of Medicine family medicine physician Ranit Mishori, M.D., M.H.S., supports the use of the vaccine in males. “In addition to preventing genital warts, vaccinating males against HPV might help prevent its spread to those who have not been vaccinated.”
Mishori reports having no personal financial interest related HPV vaccines.
Georgetown University is the owner of intellectual property on which HPV vaccines were developed. Georgetown receives financial benefit from commercial sales.
About Georgetown University Medical Center
Georgetown University Medical Center is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through MedStar Health). GUMC’s mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis — or “care of the whole person.” The Medical Center includes the School of Medicine and the School of Nursing & Health Studies, both nationally ranked; Georgetown Lombardi Comprehensive Cancer Center, designated as a comprehensive cancer center by the National Cancer Institute; and the Biomedical Graduate Research Organization (BGRO), which accounts for the majority of externally funded research at GUMC including a Clinical Translation and Science Award from the National Institutes of Health. In fiscal year 2010-11, GUMC accounted for 85 percent of the university’s sponsored research funding.